Market Signal Briefing

Memecoins rode the broader cryptocurrency market rally on Tuesday, extending their impressive run this year.

Memecoins Rejoice On Crypto Bill ProgressFrog-themed Pepe lifted over 18%, claiming the top spot among large-cap gainers. The Ethereum (CRYPTO: ETH)-based memecoin has rallied nearly 70% since the beginning of the year.

Solana (CRYPTO: SOL)-based Bonk (CRYPTO: BONK) followed Pepe with a 14% uptick, stretching its year-to-date returns beyond 56%.

Dogecoin, the world’s largest memecoin, joined in, rallying over 8% in the last 24 hours, while Shiba Inu (CRYPTO: SHIB) lifted 5.80%. The two heavyweights are up more than 25% year to date.

CryptocurrencyGains +/-Price (Recorded at 8:20 p.m. ET)Pepe PEPEBonk BONK
               Floki FLOKI             Dogecoin DOGE       Official TrumpTRUMP             24-Hour YTD Gains +/-(CRYPTO: )+18.27%+68.31%$0.000006781(CRYPTO: )+14.17%+56.08%$0.00001165(CRYPTO: )            +9.01%+24.87%$0.00005518(CRYPTO: )                 +8.51%+26.62%$145.52 (CRYPTO: )            +6.78%+19.45%$5.73The total memecoin market capitalization expanded 8.19% in the last 24 hours to $47 billion. Such levels were last seen two months ago.

Can Memecoins Stage A Lasting Comeback?The upsurge came after the Senate Banking Committee released a draft bill for the cryptocurrency market structure bill, which will treat altcoins the same way regulators currently treat Bitcoin (CRYPTO: BTC), as commodities, not securities.

After the bloodbath in 2025, bulls are crossing their fingers for a memecoin rally that actually sticks around.

The total memecoin capitalization collapsed from $94.92 billion to $37.79 billion last year, marking a 60% decline.

Photo Courtesy: DennisF on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Bitcoin has been locked in a tight consolidation range since late November, frustrating traders and fueling growing speculation about a major move ahead. Volatility has compressed, price has stabilized near key psychological levels, and market participants are increasingly divided on what comes next. Some analysts argue that this prolonged consolidation is laying the groundwork for a renewed upside recovery, while a broader consensus warns that Bitcoin could still face another leg lower before a sustainable trend emerges.

Adding to this uncertainty, top analyst Darkfost points to an important and potentially concerning on-chain development: the first signs of long-term holder (LTH) capitulation are beginning to surface. The last time Bitcoin traded at similar price levels was in April 2025, roughly nine months ago. Since then, a large portion of market participants accumulated BTC at higher prices and have continued to hold through the recent correction.

Today, many of those investors are sitting on unrealized losses. As a reminder, Bitcoin held for more than six months is classified as long-term holder supply, typically associated with higher conviction and lower sensitivity to short-term price moves. When this cohort begins to show signs of stress, it often marks a critical phase in the market cycle.

Whether this emerging LTH pressure becomes a brief shakeout or evolves into broader capitulation could play a decisive role in shaping Bitcoin’s next major move.

Early Signs of Long-Term Holder Capitulation Emerge What we are currently observing on the Long-Term Holder SOPR (Spent Output Profit Ratio) is a behavior that typically appears during bear market phases. LTH SOPR measures whether coins held for more than six months are being sold at a profit or a loss, offering insight into conviction among the most resilient cohort of Bitcoin investors.

Bitcoin Long-Term Holders SOPR High or Low Profit | Source: CryptoQuant In recent days, LTH SOPR briefly dipped below the critical 1.0 level. This signals that some long-term holders—most likely the younger segment of this group—have begun to capitulate by selling at a loss. Historically, such moves reflect rising stress among holders who bought closer to cycle highs and are now facing prolonged drawdowns.

For now, however, this behavior remains limited. The 30-day moving average of LTH SOPR still stands at a healthy 1.18, meaning long-term holders have realized an average profit of 18% over the past month. While this confirms that broad-based capitulation has not yet materialized, it is worth noting that this level is well below the annual average near 2.0, indicating a clear slowdown in realized profits.

A deeper deterioration would be bearish in the short term, signaling expanding sell pressure. Conversely, declining realized profits may also suggest that traders are gradually exhausting selling pressure. For a bullish continuation to develop, LTH SOPR would need to stabilize and begin trending higher again, confirming renewed confidence among long-term holders.

Bitcoin Price Consolidates Below Key Resistance Bitcoin continues to trade within a well-defined consolidation range after the sharp correction from the October highs. On the weekly chart, price is holding just below the $92,000–$94,000 resistance zone, an area that previously acted as support before the breakdown. This level now represents a key inflection point for market structure.

BTC consolidates above weekly support level | Source: BTCUSDT chart on TradingView Despite the recent volatility, Bitcoin remains above its rising 200-day moving average, which continues to slope upward near the mid-$80,000 region. This suggests that the broader trend remains constructive, even as short-term momentum has weakened. The 100-day moving average has flattened, reflecting a loss of upside momentum, while the 50-day average is still attempting to stabilize after rolling over during the sell-off.

Price action over the past several weeks shows a series of higher lows, indicating that buyers are gradually stepping in and absorbing selling pressure. However, volume has declined during this consolidation, signaling a lack of strong conviction from either side of the market. This behavior is typical of compression phases that often precede larger directional moves.

A sustained break and weekly close above $94,000 would signal renewed strength and open the door for a move toward the $100,000–$105,000 range. Conversely, failure to hold above the $86,000–$88,000 support zone would increase downside risk and shift focus toward deeper retracements. For now, Bitcoin remains in balance, building tension for its next decisive move.

Featured image from ChatGPT, chart from TradingView.com 

Coinbase Custody serves as the custodian for the fund’s digital assets, while Bitwise acts as sponsor and manager. Key Takeaways The Bitwise Chainlink ETF gets approval for listing on NYSE Arca. Trading for the ETF could start as soon as tomorrow. Bitwise’s Chainlink ETF has been cleared for listing on NYSE Arca following regulatory approval. The product could begin trading as early as tomorrow.

The Bitwise Chainlink ETF is designed to offer investors exposure to the price of Chainlink (LINK), the 20th largest crypto asset by market capitalization, through a traditional brokerage account that aims to lower operational and custody barriers for investors who want exposure to the asset without holding or managing tokens themselves.

The fund will directly hold LINK, with shares set to trade on NYSE Arca under the ticker CLNK. It will not engage in staking; however, Bitwise plans to seek approval to add staking as a secondary objective in the future, which could allow the trust to earn additional LINK over time.

The ETF charges a 0.34% management fee. For the first three months after listing, Bitwise will waive the full sponsor fee on the first $500 million of assets, temporarily reducing costs for early investors.

Chainlink is a decentralized oracle network that enables smart contracts on blockchains to securely interact with external data sources and off-chain systems.

LINK was trading at $14 at press time, up 7.5% in the last 24 hours, per CoinGecko. The gains follow a market-wide rebound earlier today that lifted Bitcoin to $96,000.

The Bitwise Chainlink ETF is the second US spot fund tied to LINK, approved shortly after Grayscale converted its Chainlink Trust into a spot ETF (GLNK) late last month. The GLNK fund has reached $87.5 million in assets, per the latest disclosure.

Disclaimer

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

U.S. Senator Elizabeth Warren has called on the country’s banking regulators to temporarily stop considering a bank charter application by World Liberty. This is primarily because the company is connected with President Donald Trump.

Warren Warns of World Liberty Charter Application Senator Elizabeth Warren has written a stern letter to the Office of the Comptroller of the Currency (OCC). She demanded that a review of a national trust bank charter application from WLFI be stopped immediately. The crypto company was co-founded by President Trump and members of his family.

In her letter to the OCC’s Comptroller Jonathan Gould, Warren stated that the continued review by the OCC may have a negative effect on the integrity of the federal banking oversight process.

She referred to the warnings that she issued over the summer. She had asked how the agency could ensure that the financial interests of the president do not get reflected in the regulatory decisions that it makes. When that happened, Gould said that it was purely speculative at that time.

Warren argues that these fears have come to fruition. She stated signing the World Liberty application means the President will be in a position where he can indirectly control his own financial business through a national regulator, whom he will be able to remove at will.

“If the application is approved, you would promulgate rules that influence the profitability of the President’s company. You would also be responsible for directly supervising and enforcing the law against the President’s company and its competitors.”

The controversy comes after WLFI confirmed the filing of a formal application with the federal government to obtain a nationally chartered trust bank license. The company has also formed a new subsidiary, WLTC Holdings LLC, and filed a de novo application with the OCC.

Warren asked in the letter that the OCC temporarily halt its review of the application. She also said this should remain until President Trump had entirely divested himself of his World Liberty interests.

Wider Criticism of Trump’s Crypto Involvement Expands This comes against the backdrop of a growing public concern with Trump’s growing involvement with digital currencies. Charles Hoskinson recently expressed his lack of confidence in the current political direction being taken by the industry.

These warnings have also appeared in November of the previous year. A report was released by Jamie Raskin in the capacity of the Democratic Party Report Staff. It suggested that Trump took advantage of his investments in crypto like World Liberty in order to accumulate wealth.

President Trump is also named, together with his other sons Barron, Eric, and Donald Trump Jr., as one of the co-founders of this platform. Based on public disclosures, WLFI has garnered billions of dollars in value from the crypto activities.

Corporate digital asset treasuries (DATs) added a net 260,000 Bitcoin to their balance sheets over the past six months, far outpacing the estimated 82,000 coins mined over the same period. 

Over the past six months, Bitcoin (BTC) treasuries held by public and private companies have increased from approximately 854,000 BTC to 1.11 million BTC, on-chain analytics provider Glassnode reported on Tuesday.

This equates to an expansion of around 260,000 BTC, worth roughly $25 billion at current market prices, or 43,000 BTC per month.

The growth in treasuries highlights “the steady expansion of corporate balance-sheet exposure to Bitcoin,” stated Glassnode.

Bitcoin miners, which produce on average 450 BTC per day, mined around 82,000 coins over the same period, which could indicate a favorable supply-demand dynamic at play.

Bitcoin DAT balances increased 30% in six months. Source: GlassnodeStrategy has 60% of the total BTC balanceThe lion’s share of the 1.2 million BTC held in public and private company treasury balances is held by Michael Saylor’s Strategy.

Strategy currently holds 687,410 BTC, or 60% of the total, worth around $65.5 billion at current market prices. 

The firm resumed its purchases this month after a brief hiatus, revealing that it acquired an additional 13,627 BTC between January 5 and 11 in its largest purchase since July.

The second-largest corporate Bitcoin DAT is MARA Holdings with 53,250 BTC worth around $5 billion, according to Bitcoin Treasuries.  

Bitcoin ETFs could add to demand Spot Bitcoin exchange-traded funds could add to this supply-and-demand dynamic if the inflow trend continues this year. “Bitcoin’s price will go parabolic if ETF demand persists long-term,” said Bitwise chief investment officer Matt Hougan on Tuesday.

“Since ETFs debuted in Jan 2024, they’ve been buying more than 100% of the new supply of bitcoin. But the price hasn't gone parabolic, because existing holders have been willing to sell. If ETF demand persists - and I think it will - eventually, these sellers will run out of ammo.”Spot BTC ETFs in the US saw net inflows of almost $22 billion in 2025, with BlackRock’s iShares Bitcoin Trust (IBIT) taking the lion’s share. 

However, they have had a mixed start to 2026 with current data showing $1.9 billion inflows and $1.38 billion outflows, resulting in a net aggregate inflow of just over $500 million.

Magazine: Trump rules out SBF pardon, Bitcoin in ‘boring sideways’: Hodler’s Digest

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

The Coinbase premium index remains negative, indicating a relatively weaker U.S. demand.

Lower inflation eased pressure on bond yields and improved liquidity conditions, a setup that has historically favored crypto and other risk assets.

Solana started a fresh increase above the $142 zone. SOL price is now consolidating above $142 and might aim for more gains above the $150 zone.

SOL price started a fresh upward move above the $142 and $145 levels against the US Dollar. The price is now trading above $142 and the 100-hourly simple moving average. There is a bullish trend line forming with support at $140 on the hourly chart of the SOL/USD pair (data source from Kraken). The pair could extend gains if it clears the $150 resistance zone. Solana Price Starts Fresh Surge Solana price started a decent increase after it settled above the $135 zone, like Bitcoin and Ethereum. SOL climbed above the $140 level to enter a short-term positive zone.

The price even smashed the $142 resistance. The bulls were able to push the price above $145. A high was formed at $148, and the price is now consolidating gains. There was a minor decline below the 23.6% Fib retracement level of the recent upward move from the $138 swing low to the $148 high.

Solana is now trading above $142 and the 100-hourly simple moving average. Besides, there is a bullish trend line forming with support at $140 on the hourly chart of the SOL/USD pair.

Source: SOLUSD on TradingView.com On the upside, the price is facing resistance near $148. The next major resistance is near the $150 level. The main resistance could be $155. A successful close above the $155 resistance zone could set the pace for another steady increase. The next key resistance is $162. Any more gains might send the price toward the $170 level.

Downside Correction In SOL? If SOL fails to rise above the $148 resistance, it could start another decline. Initial support on the downside is near the $144 zone. The first major support is near the $143 level or the 50% Fib retracement level of the recent upward move from the $138 swing low to the $148 high.

A break below the $143 level might send the price toward the $140 support zone and the trend line. If there is a close below the $140 support, the price could decline toward the $135 support in the near term.

Technical Indicators

Hourly MACD – The MACD for SOL/USD is gaining pace in the bullish zone.

Hourly Hours RSI (Relative Strength Index) – The RSI for SOL/USD is above the 50 level.

Major Support Levels – $144 and $140.

Major Resistance Levels – $148 and $150.

NEW YORK and NEW ORLEANS, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE), if they purchased or otherwise acquired the Company’s securities between January 27, 2025 to October 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

What You May Do

If you purchased securities of Alexandria and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-are/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 26, 2026.

About the Lawsuit

Alexandria and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On October 27, 2025, post-market, the Company disclosed financial results for the third quarter of fiscal year 2025 that were below expectations, including cuts to its FFO guidance for the full-year 2025, due to lower occupancy rates, slower leasing activity and most notably, a real estate impairment charge of $323.9 million with $206 million attributed to its LIC property.

On this news, the price of Alexandria’s shares fell from a closing market price of $77.87 per share on October 27, 2025 to $62.94 per share on October 28, 2025, a decline of about 19% in the span of just a single day.

The case is Warren Hern v. Alexandria Real Estate Equities, Inc., et al., No. 25-cv-11319.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Labcorp Holdings Inc. (LH) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 7:30 PM EST

Company Participants

Adam Schechter - President, CEO & Chairman
Julia Wang - CFO & Executive VP

Conference Call Participants

Lisa Gill - JPMorgan Chase & Co, Research Division

Presentation

Lisa Gill
JPMorgan Chase & Co, Research Division

Good afternoon, and welcome. My name is Lisa Gill, and I head up healthcare services here at JPMorgan. It is with great pleasure this afternoon that I will host a fireside chat with LabCorp. With LabCorp this afternoon I have to my right, the CEO, Adam Schechter; and to Adam's right is CFO, Julia Wang. So with that, Adam, welcome. Nice to see you.

Adam Schechter
President, CEO & Chairman

Happy New Year. It's nice to be back.

Question-and-Answer Session

Lisa Gill
JPMorgan Chase & Co, Research Division

Happy New Year. As I look back on '25, and I know we still don't have the fourth quarter, but if I look at the fundamentals, solid core fundamentals, you had nice M&A integration support, improved organic growth. Is there something you want to highlight to investors that you're particularly proud of as you look back at 25?

Adam Schechter
President, CEO & Chairman

Sure. So first of all, I hope everybody had a nice new year. It's a pleasure to be with you all today.

2025 was a tremendous year for LabCorp. If you look strategically, we said we were going to focus on 4 core therapeutic areas: oncology, women's health, autoimmune and neurology. We launched over 100 tests last year, and the majority of them were in those 4 areas. Those areas we expect to grow 2 to 3x faster than the rest of the diagnostic market. So it's a tremendous opportunity for growth.

We also said that

Park Aerospace Corp. (PKE) Q3 2026 Earnings Call January 13, 2026 5:00 PM EST

Company Participants

Brian Shore - Chairman & CEO
Mark A. Esquivel - President & COO

Presentation

Operator

Good morning. My name is Shamali, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Park Aerospace Corp. Third Quarter Fiscal Year 2026 Earnings Release Conference Call and Investor Presentation. [Operator Instructions] Thank you.

At this time, I will turn today's call over to Mr. Brian Shore, Chairman and Chief Executive Officer. Mr. Shore, you may begin your conference.

Brian Shore
Chairman & CEO

Thank you, operator. Welcome, everybody. Happy New Year. This is Brian and welcome to the Park Aerospace Corp. Fiscal Year 2026 Third Quarter Investor Conference Call. I have with me, as usual, Mark Esquivel, our President and CEO; Correction, COO. I gave you a promotion there, Mark, sorry. And just so a little housekeeping stuff. We announced -- released our third quarter earnings release or published our third quarter earnings release right after the close. You want to get a hold of that because in the release, there is a link information to access the presentation we're about to go through. Presentation is also posted on our website. So we have a lot to cover want to get started. We have our dilemma. We have a lot of new investors, a lot of veteran investors.

So how much do we cover the background stuff is always a little bit of an issue. We'll do the best we can. Also, I just want to mention that we did file an S-3 registration statement with the SEC after the close as well. So we're going to get started with the presentation. We have a lot to cover. Obviously, at the end of our presentation, we'll be

January 13, 2026 – TheNewswire - Vancouver, BC, Canada – Kirkstone Metals Corp. (the “Company” or “Kirkstone”) (TSXV: KSM, FWB:VO0) announces that it has granted an aggregate of 1,200,000 stock options at $3.71 per option share to Directors, Officers and Consultants.

The Company’s shareholders ratified and approved all resolutions presented at the Company’s recently held Annual General Meeting, including the approval of the Company’s new omnibus equity incentive plan (the “Incentive Plan.”) to replace the Company’s existing stock option plan.  The Incentive Plan continues to limit the number of outstanding incentive securities to 10% of the issued and outstanding common shares of the Company at any given time but now provides for the grant of other types of incentive securities such as restricted share units (“RSUs”), deferred share units and stock options.

The Company’s shareholders fixed the number of directors at four (4), elected all directors standing for election for the ensuing year and approved the re-appointment of the Company’s auditors.

About Kirkstone Metals Corp.

Kirkstone Metals Corp. is a Canadian mineral exploration company focused on uranium exploration within established mining jurisdictions in Canada.

For more information on the Company, please contact

Investor Relations, Ray Lagace at (604) 418-6950‬ or email: [email protected].

On Behalf of the Board of Directors of Kirkstone Metals Corp.

Clive Massey
Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann Purchase Licensing Rights, opens new tab

SHANGHAI, Jan 14 (Reuters) - BGI Genomics (300676.SZ), opens new tab and Roche Diagnostics (ROG.S), opens new tab have rolled out tests for Alzheimer's disease in China, the companies said, in an effort to expand access to easier-to-use diagnosis and monitoring choices for patients with the brain-wasting condition.

In a statement, BGI Genomics said doctors are using a blood test it developed, opens new tab as an auxiliary tool in Guangzhou, Qingdao, Shenzhen and Wuhan to evaluate the disease's progression and the risk of onset.

Sign up here.

Switzerland's Roche also said in a statement that its team in China was working with a local regulatory authority to make its own test measuring pTau181, a key protein associated with Alzheimer's disease, available to patients in Boao, Hainan province.

The Roche test was put into clinical use at a hospital in Boao, the official Hainan Daily reported on Monday. Roche did not respond to questions related to the report.

Blood tests could speed up diagnosis of the disease and make it easier to access treatments such as Biogen (BIIB.O), opens new tab and Eisai's (4523.T), opens new tab Leqembi and Eli Lilly's (LLY.N), opens new tab Kisunla, since traditional tests are often costly or uncomfortable.

Other options to detect Alzheimer's include a spinal tap, which requires an invasive puncture to collect spinal fluid, or an expensive PET brain scan.

BGI Genomics said its test cannot be used as standalone evidence for an Alzheimer's diagnosis and treatment, citing a possibility of a small number of failures, but doctors said it was helpful for early screening.

Roche said a negative test for pTau181 with its product meant "most people can avoid further unnecessary investigations for Alzheimer’s using CSF (cerebrospinal fluid) or PET and can be put on the appropriate pathway for their condition."

Editing by Miyoung Kim and Thomas Derpinghaus

Our Standards: The Thomson Reuters Trust Principles., opens new tab

NEW YORK and NEW ORLEANS, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in DeFi Technologies Inc. (“DeFi” or the “Company”) (NasdaqCM: DEFT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of DeFi Technologies who were adversely affected by alleged securities fraud between May 12, 2025 and November 14, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqcm-deft/

DeFi Technologies investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqcm-deft/ to learn more.

CASE DETAILS: According to the Complaint, on November 13, 2025, post-market, the Company announced its financial results for the third quarter of 2025, disclosing a nearly 20% decline in revenue, well below market expectations, and also significantly lowered its 2025 revenue forecast, from $218.6 million to approximately $116.6 million, due to “a delay in executing DeFi Alpha arbitrage opportunities previously forecasted due to the proliferation of [DAT] companies and the consolidation in digital asset price movement in the latter half of 2025.” On this news, the price of DeFi’s shares fell $0.40 per share, or 27.59%, over the following two trading sessions, to close at $1.05 per share on November 17, 2025.

The case is Linked to Partners LLC v. DeFi Technologies Inc., et al., No. 25-cv-06637.

WHAT TO DO? If you invested in DeFi Technologies and suffered a loss during the relevant time frame, you have until January 30, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

HomeETFs and Funds AnalysisClosed End Funds Analysis

SummaryNuveen Preferred & Income Opportunities Fund offers a 9% yield, primarily from investment-grade preferred stocks concentrated in financials.JPC's leveraged structure enhances yield but introduces cyclical risk and sensitivity to rate cycles, evidenced by dividend cuts during disruptions.Shares currently trade near NAV, with the yield at historically high levels but lacking a growth element; capital preservation is key.JPC appears fairly valued; a more attractive entry would be at a higher yield, while existing holders have seen positive long-term total returns. SaskiaAcht/iStock via Getty Images

Nuveen Preferred & Income Opportunities Fund (JPC) offers a 9% yield on a preferred stock portfolio. It's not bad income, but JPC is very much cyclical, and so investors might want a better price before diving in.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK and NEW ORLEANS, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 20, 2026 to file lead plaintiff applications in a securities class action lawsuit against Klarna Group plc (NYSE: KLAR), if they purchased the Company’s securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Klarna’s September 2025 initial public offering (the “IPO”). This action is pending in the United States District Court for the Eastern District of New York.

What You May Do

If you purchased securities of Klarna as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-klar/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 20, 2026.

About the Lawsuit

Klarna and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company materially understated the risk that its loss reserves would materially increase within a few months of the IPO, which they either knew of or should have known of given the risk profile of many individuals agreeing to the Company’s buy now, pay later (“BNPL”) loans; and (ii) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.

The case is Nayak v Klarna Group Plc., et al., No. 25-cv-7033.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Analyst’s Disclosure:I/we have a beneficial long position in the shares of VICI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

BioNTech SE (BNTX) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 5:15 PM EST

Company Participants

Ugur Sahin - Co-Founder, CEO & Chair of the Management Board
Ramón Zapata-Gomez - CFO & Member of Management Board

Conference Call Participants

Jessica Fye - JPMorgan Chase & Co, Research Division

Presentation

Jessica Fye
JPMorgan Chase & Co, Research Division

Great. Good afternoon. Welcome, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference today with BioNTech.

First, you're going to hear a presentation from the company, and then we're going to go into some Q&A. So if you have a question in the room, just raise your hand and someone will bring you a microphone or alternatively, you can submit it online, and I'll read it off the iPad up here.

So with that out of the way, I'm pleased to introduce BioNTech's CEO, Ugur Sahin.

Ugur Sahin
Co-Founder, CEO & Chair of the Management Board

Hello, everyone. It's a pleasure to be here. I would like to welcome everyone here and online. These are the typical disclaimers. And I would like to start with the -- can we just change what is on the monitor?

Okay. So let me start with the status quo that we have here. While BioNTech has grown and evolved, our vision has remained the same, namely translating science into survival. From the current situation, from today's perspective, we have so far delivered together with our partner, Pfizer, 5 billion doses of vaccines worldwide. We have engaged with our mRNA technology in global health programs, have 6 programs here running. Most importantly, we pivoted back to oncology, have currently 25 clinical trials ongoing and 16 clinical programs. We have also integrated AI and advanced GMP manufacturing capabilities, providing us the opportunity to rapidly translate science into clinical trials.

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —

— Savolitinib and osimertinib combination approved in China in June 2025 —

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR tyrosine kinase inhibitor (“TKI”) therapy.

Savolitinib is an oral, potent and highly selective MET TKI being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is a third-generation, irreversible EGFR TKI. Based on interim data from SACHI, the savolitinib and osimertinib combination was granted regulatory approval in China in June 2025. 

“The SACHI trial, now published in The Lancet, provides compelling evidence that savolitinib combined with osimertinib can transform outcomes for patients with EGFR-mutated NSCLC with MET amplification. These findings highlight the combination’s ability to address MET amplification, a critical resistance mechanism, offering clinically meaningful improvements for this challenging patient population,” said Professor Shun Lu, Chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and co-leading Principal Investigator of the SACHI trial. “We are particularly encouraged by the consistent benefits observed in patients previously treated with third-generation EGFR-TKIs, where savolitinib plus osimertinib offers a continued all-oral regimen, providing a convenient and well-tolerated solution for this underserved population.” Professor Jie Wang of Cancer Hospital, Chinese Academy of Medical Sciences also served as co-leading Principal Investigator of the SACHI trial.

About the SACHI Phase III Trial

In January 2025, the Independent Data Monitoring Committee (IDMC) of SACHI considered that the study had met the pre-defined primary endpoint of progression-free survival (“PFS”) in a planned interim analysis and, as a result, enrollment into the study has concluded. As of the interim analysis data cut-off of August 30, 2024, a total of 211 patients were randomized to receive the savolitinib and osimertinib combination (n=106) or chemotherapy (n=105). In the intention-to-treat (“ITT”) population, the median PFS assessed by investigator was 8.2 months (95% confidence interval [“CI”] 6.9–11.2) with savolitinib plus osimertinib, compared to 4.5 months (95% CI 3.0–5.4) with chemotherapy (hazard ratio [“HR”] 0.34; 95% CI 0.23–0.49; p<0.0001). The independent review committee (“IRC”) assessed median PFS was 7.2 vs 4.2 months, respectively (HR 0.40; 95% CI 0.28–0.59; p<0.0001).

The investigator-assessed objective response rate (“ORR”) was 58% in the savolitinib plus osimertinib arm compared to 34% for patients in the chemotherapy arm. The disease control rate (DCR) was 89% vs 67%, and the median duration of response (DoR) was 8.4 vs 3.2 months, respectively. The median time to response (TTR) was similar between two arms (1.4 vs 1.5 months). Overall survival (“OS”) data were still evolving and not mature at the time of the interim analysis, with only 37% and 43% OS maturity. At median OS follow-up duration of 17.7 months in the ITT population, savolitinib plus osimertinib arm reported median OS of 22.9 months vs 17.7 months in the chemotherapy arm (HR 0.84). 55 (52%) patients in the chemotherapy arm received subsequent MET inhibitor therapy after disease progression, with 45 (43%) crossing over to savolitinib-osimertinib and ten (10%) subsequently received MET inhibitor. In sensitivity analyses of OS to adjust for this crossover, the OS benefits of the savolitinib plus osimertinib arm were more significant, with HRs ranging from 0.24 to 0.62.

In the third-generation EGFR TKI–naïve subgroup population (i.e. patients previously treated with a first- or second-generation EGFR TKI), investigator-assessed median PFS was 9.8 vs 5.4 months (HR 0.34; 95% CI 0.21–0.56; p<0.0001). Efficacy outcomes in the third-generation EGFR-TKI–treated subgroup were comparable with those in the ITT population. In this subgroup, the investigator-assessed median PFS was 6.9 vs 3.0 months (HR 0.32; 95% CI 0.18–0.57; p<0.0001), and IRC-assessed median PFS was 6.9 vs 3.0 months (HR 0.32; 95% CI 0.18–0.58; p<0.0001).

The safety profile of the savolitinib and osimertinib combination was tolerable and no new safety signals were observed. Treatment-emergent adverse events (“TEAEs”) of Grade 3 or above occurred in 57% of patients in the savolitinib plus osimertinib arm compared to 57% (55 of 96) for patients in the chemotherapy arm. Common Grade ≥3 TEAEs (≥10% in either arm) included decreased neutrophil count (14% vs 26%), decreased white blood cell count (7% vs 13%), and anemia (4% vs 23%).

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths.1 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.2 The majority of NSCLC patients (approximately 75%) are diagnosed with advanced disease, and approximately 10-15% of NSCLC patients in the US and Europe and up to 40-50% of patients in Asia have EGFR-mutated (“EGFRm”) NSCLC.3,4,5,6,7

MET is a tyrosine kinase receptor that has an essential role in normal cell development. MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is one of the mechanisms of de novo or acquired resistance to EGFR TKI for metastatic EGFRm NSCLC.8,9

About ORPATHYS®

ORPATHYS® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS® is approved in China and is marketed by AstraZeneca for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS® is also approved in China for the treatment of patients with locally advanced or metastatic EGFRm-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy, in combination with TAGRISSO®.

It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers as a single treatment and in combination with other medicines.

About TAGRISSO®

TAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system (CNS) metastases. TAGRISSO® (40mg and 80mg once-daily oral tablets) has been used to treat more than one million patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO® as a treatment for patients across multiple stages of EGFRm NSCLC.

There is an extensive body of evidence supporting the use of TAGRISSO® in EGFRm NSCLC, and it is the only targeted therapy shown to improve patient outcomes across all stages of the disease.

In late-stage disease, TAGRISSO® demonstrated improved outcomes as monotherapy in the FLAURA Phase III trial and in combination with chemotherapy in the FLAURA2 Phase III trial. TAGRISSO® is also being investigated in this setting in combination with ORPATHYS® (savolitinib) in the SAFFRON Phase III trial and in combination with DATROWAY® (datopotamab deruxtecan or Dato-DXd) in the TROPION-Lung14 and TROPION-Lung15 Phase III trials. 

TAGRISSO® also showed improved outcomes in early-stage disease in the NeoADAURA and ADAURA Phase III trials and in locally advanced stages in the LAURA Phase III trial. As part of AstraZeneca’s ongoing commitment to treating patients as early as possible in lung cancer, TAGRISSO® is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.

About ORPATHYS® and TAGRISSO® Combination Development in EGFR-mutated NSCLC

This combination represents a promising chemotherapy-free oral treatment strategy to address mechanisms of resistance in this setting. Among patients who experience disease progression following treatment with a third-generation EGFR TKI, approximately 15-50% present with MET aberration, depending on the sample type, detection method and assay cut-off used. TAGRISSO® is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. Treatment with ORPATHYS® in combination with TAGRISSO® has been studied extensively in these patients in the TATTON study (NCT02143466) and the SAVANNAH single-arm Phase II study (NCT03778229). Strong data from SAVANNAH presented at the 2025 European Lung Cancer Congress (ELCC) demonstrated high, clinically meaningful and durable ORR, with consistent safety results. The encouraging results led to the initiation of several randomized Phase III trials in this setting including the SACHI trial in China (NCT05015608) and the global SAFFRON trial (NCT05261399), as well as the SANOVO trial in China (NCT05009836).

SACHI: This Phase III trial in China evaluated the combination of ORPATHYS® and TAGRISSO® compared to platinum-based doublet chemotherapy for the treatment of patients with EGFRm, MET-amplified locally advanced or metastatic NSCLC following progression on treatment with an EGFR TKI. Results were presented at the 2025 ASCO Annual Meeting. The treatment combination received approval in China in June 2025.

SAFFRON: This ongoing global Phase III trial is to evaluate the combination of ORPATHYS® and TAGRISSO® compared to platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following progression on treatment with TAGRISSO®. This received Fast Track Designation from the US FDA and enrollment was completed in October 2025. We look forward to completing this trial to support potential US and other global registration filings.

SANOVO: This ongoing Phase III trial in China is to evaluate the combination of ORPATHYS® and TAGRISSO® compared to TAGRISSO® monotherapy in previously untreated patients with locally advanced or metastatic NSCLC with EGFRm and MET overexpression. Enrollment was completed in August 2025.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS®, the further clinical development for ORPATHYS®, its expectations as to whether any studies on ORPATHYS® would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in other jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS® for a targeted indication; and HUTCHMED and/or its partner’s ability to fund, implement and complete its further clinical development and commercialization plans for ORPATHYS®, and the timing of these events. In addition, as certain studies rely on the use of other drug products such as TAGRISSO® as combination therapeutics with ORPATHYS®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 /[email protected]  Media Enquiries FTI Consulting –+44 20 3727 1030 /[email protected] Atwell / Tim Stamper+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) /[email protected]  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500  Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000     1World Health Organization. International Agency for Research on Cancer. All cancers fact sheet. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Accessed November 2022.2American Cancer Society. What is Lung Cancer? Available at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed November 2022.3Knight SB, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9): 170070.4Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27.5Zhang Y, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48).6Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in 11. Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013:6;2800-12.7Gou LY, et al. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China. Lung Cancer: Targets and Therapy. 2014; 5; 1–9.8Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074).9Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. Journal of Hematology & Oncology. 2019;63. 

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Dixit v Smart Digital Group Limited, et.al, Case 1:26-cv-00296, on behalf of persons and entities that purchased or otherwise acquired Smart Digital Group Limited (“SDM” or the “Company”) (NASDAQ: SDM) securities between May 5, 2025 and September 26, 2025, at 9:34 AM EST, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Investors are hereby notified that they have until March 16, 2026 to move the Court to serve as lead plaintiff in this action.

You may obtain a copy of the complaint on our website.

Smart Digital Group Limited, based in Singapore, provides event planning and execution services, which consist of drafting and customizing event marketing strategies, and engaging event sponsors.

Throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and the true nature of the trading activity in the securities. Specifically, Defendants failed to disclose to investors that: (1) SDM was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) insiders and/or affiliates used and/or intended to use offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) SDM’s public statements and risk disclosures omitted any mention of realized risk of fraudulent trading or market manipulation used to drive the Company’s stock price; (4) as a result, SDM securities were at unique risk of a sustained suspension in trading by either or both of the United States Securities and Exchange Commission (“SEC”) and NASDAQ; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis.

On September 26, 2025, the Company’s stock price fell 86.4%, to close at $1.85 per share, following an intraday halt by the NASDAQ Stock Market (the “NASDAQ”) due to unusually high volatility.

Before trading opened the next day, the SEC suspended trading in SDM securities from September 29, 2025, through October, 10, 2025, due to “potential manipulation” in the Company’s securities “effectuated through recommendations made to investors by unknown persons via social media to purchase the securities of SDM, which appear to be designed to artificially inflate the price and volume of the securities of SDM.”

With the SEC suspension scheduled to expire, on October 11, 2025, NASDAQ suspended trading in SDM securities pending a request for additional information. The shares remain halted.

Why Wolf Haldenstein Adler Freeman & Herz LLP?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

Phone: (800) 575-0735 or (212) 545-4774Email: [email protected] Person: Gregory Stone, Director of Case and Financial Analysis Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

A combination of protocol-level upgrades, stablecoin activity, and a shift in crypto sentiment has helped push Ether wallet creation to its highest levels in history. 

Over the last week, an average of 327,000 new wallets have been created per day, with Sunday recording the highest number ever for a single day at over 393,000, Santiment analysts said in an X post on Tuesday.

New wallets can signal that fresh users, developers, or institutions are entering the ecosystem.

Data also shows that non-empty Ether wallets are now at 172.9 million, which is also at an all-time high.

Ether (ETH) is currently $3,330, up 7.5% in the last 24 hours after moving between $3,068 and $3,292 in the last week, according to CoinGecko.

An average of 327,000 new Ethereum wallets have been created every day over the last week. Source: SantimentSantiment analysts suggest the surge in new wallets could partly be because of the Fusaka upgrade in December, which “made using Ethereum cheaper and easier,” by improving data handling on-chain and cutting the cost of posting information from L2 networks back to Ethereum.

“This reduced fees and made interacting with apps and rollups smoother, encouraging many new users to open wallets and start using the network,” they said.

Crypto sentiment shift and stablecoinsAlong with the major protocol upgrade, Ethereum may also be benefiting from general sentiment improvement as investors and developers reset their strategies in the new year. 

Santiment analysts said holder sentiment shifted from negative to neutral and positive in mid-December, “which often coincides with more retail users signing up and creating addresses.”

There was also more interest from new users to enter the ecosystem to explore DeFi, non-fungible tokens and other apps toward the end of the year. 

A spike in stablecoin transfers on Ethereum in late 2025 could also be a factor, as it showed the “network was being actively used for payments and settlements,” according to Santiment.

“This kind of real financial activity tends to bring in new participants who create wallets to send, receive, or hold stablecoins and other tokens.”More than half of all Ether is in staking More than half of the total supply of Ether is in staking contracts, according to on-chain analytics platform Nansen. The ETH2 Beacon Deposit Contract holds over 77 million tokens, representing the total of validator stake deposits used to secure the network.

Crypto exchange Binance holds nearly 4 million Ether in its wallets on behalf of users, while fellow exchange Coinbase has around 2.3 million. 

Magazine: One metric shows crypto is now in a bear market: Carl ‘The Moon’

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

TLDR:

Upexi issues a $36 million convertible note to acquire more SOL and strengthen its balance sheet. The company’s projected holdings will exceed 2.4 million SOL tokens following the deal’s closing. The move coincides with a streak of net inflows into Solana ETFs, accumulating over $827 million. This Tuesday, Upexi, Inc. (NASDAQ: UPXI) unveiled its strategy to strengthen its position in the digital asset ecosystem. The firm entered into a securities purchase agreement with Hivemind Capital Partners for the issuance of a convertible note valued at approximately $36 million.

Under this agreement, the company will increase its Solana treasury holdings, using locked SOL tokens as consideration to collateralize the operation.

Institutional Consolidation and the Solana Ecosystem Boom The execution of this transaction is a milestone for Upexi in its goal of becoming a leading vehicle for institutional exposure to digital assets. 

With a 24-month maturity and a 1.0% interest rate, the convertible note is designed to be accretive for shareholders. According to Allan Marshall, the firm’s CEO, the objective is to surpass the 34% growth in adjusted SOL per share recorded in 2025.

Upon completion of this deal, the entity’s Solana treasury holdings will reach more than 2.4 million units, consolidating its competitive advantage.

The news comes amidst a period of notable strength for the network. While other assets show mixed flows, Solana has maintained a positive trend of institutional inflows through its spot ETFs. 

On Monday, January 12 alone, these financial products recorded inflows of $10.67 million, pushing total net assets above $1.14 billion.

The market has reacted favorably to this corporate accumulation and the steady flow of capital into exchange-traded funds. 

Currently, the asset shows great resilience, trading above $143. The strategy of expanding its Solana treasury holdings places Upexi in a privileged position to capitalize on mass adoption and the institutional interest that continues to flow into the Solana ecosystem at the start of 2026.

Bitcoin has decoupled from the global M2 supply for the first time. Here’s what could be the reason for it, according to the founder of Capriole Investments.

Bitcoin Has Diverged From The Global M2 Supply Trend In a new post on X, Capriole Investments founder Charles Edwards has talked about how Bitcoin has decoupled from the global liquidity flows recently. Below is the chart cited by Edwards, which compares the year-over-year (YoY) percentage change in BTC to that in the global M2 supply.

Looks like the two metrics have gone different ways in recent months | Source: @caprioleio on X As displayed in the graph, Bitcoin’s YoY change flatlined over 2025 while the total money supply of the world’s major economies witnessed growth, indicating BTC diverged from traditional liquidity flows.

In the past, the cryptocurrency’s YoY percentage change has generally showcased a similar trajectory to the global M2 supply. “This is the first time Bitcoin has decoupled from money supply and global liquidity flows,” noted the analyst.

What’s the reason behind this new trend? According to Edwards, it’s the threat posed by quantum computing to the network. Quantum computers are hypothesized to have the capability to break the cryptocurrency’s cryptography, with wallets from the blockchain’s early days being especially vulnerable.

It’s uncertain when quantum machines will find a breakthrough, but the Capriole founder believes BTC passed into a “Quantum Event Horizon” in 2025. “The timeframe to a non-zero probability of a quantum machine breaking Bitcoin’s cryptography is now less than the estimated time it will take to upgrade Bitcoin,” said Edwards.

In theory, a party with a sufficiently advanced quantum computer could break into old dormant wallets and dump the coins on the market. This would not only directly impact BTC’s price but could also undermine broader trust in the cryptocurrency itself.

“Money is repositioning to account for this risk accordingly,” explained the analyst. One X user countered that most investors don’t seem to agree with Edwards’ quantum timeline, suggesting that the market would be unlikely to decouple based on a view not widely shared.

“If you listen to all in bitcoin maxis on X you would think that,” Edwards replied to the user. “If you talk to real capital allocators and Bitcoin OGs in the space 7+ years in private – they are all considering this risk.”

In some other news, Bitcoin spot exchange-traded funds (ETFs) have continued to face weak demand recently, as data from SoSoValue shows.

How the weekly spot ETF netflow has changed during the last two years | Source: SoSoValue From the above chart, it’s visible that last week saw $681 million exit from the US Bitcoin spot ETFs. The new week has started with inflows so far, but it only remains to be seen whether they will continue in the coming days.

BTC Price At the time of writing, Bitcoin is floating around $92,100, up nearly 2% in the last 24 hours.

The price of the coin seems to have been consolidating | Source: BTCUSDT on TradingView Featured image from Dall-E, chart from TradingView.com

Journalist

Posted: January 14, 2026

Halfway through January, volatility is just getting started.

From a technical view, after kicking off 2026 with solid momentum, most top-cap assets have slipped into the red.

Naturally, the question is whether this is just a post-rally cooldown or the start of something deeper.

Ripple [XRP], in particular, has more at stake. Technically, it rallied over 12% from late December into early January.

To put that into perspective, that’s roughly 2x the move seen in Ethereum [ETH] over the same period.

Source: TradingView (XRP/USDT)

Given this setup, a breakdown felt almost inevitable.

CoinMarketCap data showed XRP down roughly 11% on the week, making it the weakest performer among top caps. Overhead supply was clearly stacked around $2.50, where resistance held and profit-taking kicked in.

Naturally, attention now turns to conviction. 

Speculative capital is rotating in aggressively, with a $3.58 million long position spotted. This raises the key question: Is this a risky gamble, or does the trader know something the market hasn’t priced in yet?

XRP’s liquidity wall builds as whales battle volatility Ripple is showing what traders are calling a “great divergence.”

From a technical perspective, XRP’s 11% drop this week looks like a classic post-rally shakeout, with retail locking in gains before the momentum faded. Naturally, that puts the spotlight on whales.

Notably, whale tracker showed about 219 million XRP recently moved between unknown wallets, marking a textbook risk-management move to ride out volatility and HODL long-term instead of selling in panic.

Source: X

In fact, this backs up AMBCrypto’s recent take on ongoing whale buying.

Put it all together: XRP whales are showing conviction, the last ETF saw $4.9 million in net inflows, and $22 million moved off exchanges.

The result?

A “supply shock” setup that traders are calling a great divergence.

With that in mind, XRP’s short-liquidity wall around $2.10 is shaping up as a key level. However, with solid bids, it’s only a matter of time before Ripple sweeps the cluster, making its 11% drop look like a classic “bear trap.”

Final Thoughts XRP’s 11% drop looks like a post-rally shakeout, with whales moving 219 million tokens and strong bid-side support hinting at a classic bear trap. A great divergence shows whale conviction and a potential rally setup around the $2.10 short-liquidity wall.

Ritika Gupta is a Financial Journalist and Geopolitical Analyst at AMBCrypto, specializing in the critical intersection of world politics, economic policy, and the cryptocurrency markets. Her analysis is informed by her distinguished background, which includes professional experience at major news network. She holds a Bachelor's degree in Political Science and Psychology from Gargi College, University of Delhi. This academic training provides her with a sophisticated framework for dissecting complex issues such as international regulations, government fiscal policies, and the geopolitical forces that directly influence asset valuations. At AMBCrypto, Ritika applies this expert lens to synthesize macroeconomic data and political developments, offering readers a deeper context for market movements. She excels at explaining not just what is happening in the market, but why it is happening. Her work is dedicated to providing strategic insights that empower readers to understand the complex relationship between global events and their digital assets.